ReviewAnnals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology2021
Group 2 innate lymphoid cells in nasal polyposis.
Review in Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 39 citations in OpenAlex.
- Review
- Association between fungi and postoperative recurrence in eosinophilic chronic rhinosinusitis.American journal of respiratory and critical care medicine · 2026Article
- Heterogeneity and clinical relevance of group 2 innate lymphoid cells subsets in nasal polyps.The Journal of allergy and clinical immunology · 2026Article
- Mucosal Remodeling in Chronic Rhinosinusitis with Nasal Polyps: The Role of Innate Lymphoid Cells and Reprogramming Under IL-4Rα Blockade.International journal of molecular sciences · 2026Review
- Immune-inflammatory endotypes of chronic rhinosinusitis: from epithelial alarmins to personalized therapy.Frontiers in immunology · 2026Review
- Progress in cellular mechanisms of chronic rhinosinusitis.Fundamental research · 2026Review
- The microbiota-metabolite-immune axis in the olfactory cleft microenvironment: mechanisms and therapeutic implications for dysbiosis-driven olfactory dysfunction in chronic rhinosinusitis.Frontiers in immunology · 2026Review
- Butyrate Regulating Inflammatory Responses in Chronic Obstructive Pulmonary Disease via the Gut-Lung Axis.International journal of chronic obstructive pulmonary disease · 2026Review
- Epithelial Lining Fluid Cystatin SN is a Noninvasive Biomarker for Predicting Type 2 Chronic Rhinosinusitis.Allergy · 2025Article
- The immunology of asthma and chronic rhinosinusitis.Nature reviews. Immunology · 2025Review
- Current Understanding of Epithelial-Derived Alarmins in Chronic Rhinosinusitis with Nasal Polyps.Clinical reviews in allergy & immunology · 2025Review
- Effectiveness of dupilumab treatment against refractory eosinophilic chronic rhinosinusitis.The journal of allergy and clinical immunology. Global · 2025Article
- The advance on pathophysiological mechanisms of type 2 chronic rhinosinusitis with nasal polyposis.Frontiers in allergy · 2025Review
- Role of ILC2s as Potential Effector Cells of IL25-Mediated Type 2 Inflammation in Chronic Rhinosinusitis with Nasal Polyps in China.Journal of inflammation research · 2025Article
- NOX2 mediates NLRP3/ROS facilitating nasal mucosal epithelial inflammation in chronic rhinosinusitis with nasal polyps.Heliyon · 2024Article
- Evaluation ofMolecules (Basel, Switzerland) · 2024Article
- Role of autophagy and mitophagy of group 2 innate lymphoid cells in allergic and local allergic rhinitis.The World Allergy Organization journal · 2024Article
- Exploring the immunopathology of type 2 inflammatory airway diseases.Frontiers in immunology · 2024Review
- Type 2 Biomarkers for the Indication and Response to Biologics in CRSwNP.Current allergy and asthma reports · 2023Review
- Unraveling the Role of Epithelial Cells in the Development of Chronic Rhinosinusitis.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
objectiveChronic rhinosinusitis with nasal polyps (CRSwNP) is characterized by a chronic type 2 inflammatory response in the paranasal sinuses. Group 2 innate lymphoid cells (ILC2s) are potent innate immune cells that contribute to type 2 inflammation by producing cytokines such as interleukin (IL)-4, IL-5, and IL-13. There is increasing evidence suggesting that ILC2s play an important role in the CRSwNP pathogenesis. DATA SOURCES: We reviewed published literature obtained through PubMed inquiries. STUDY SELECTIONS: Studies relevant to the presence, function, and activation of ILC2s in CRSwNP were included.
resultsNasal polyps (NPs) are one of the first tissues in which human ILC2s were discovered, and many groups have since reported that these cells are highly elevated in NPs. ILC2s in NPs are also highly activated and produce type 2 cytokines in vivo. Mediators known to activate ILC2s, including receptor activator of nuclear factor kappa-Β ligand, thymic stromal lymphopoietin, various lipid mediators (including prostaglandin D
conclusionILC2-mediated type 2 inflammation plays a crucial role in the pathogenesis of CRSwNP. Targeting the upstream mediators responsible for activating ILC2s and the downstream products that these cells release may play an important role in modifying the inflammatory response and improving clinical outcomes in CRSwNP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.